However, side effects such as gastrointestinal discomfort and mild hypoglycemia were common, and all GLP-1 are categorized as pregnancy Category C by the U.S. Food and Drug Administration (FDA), with potential implications for fetal health due to transplacental passage.<h4>Conclusion</h4>This review highlights the need for large-scale, long-term studies to establish standardized protocols and assess the safety and efficacy of GLP-1 in managing GDM, potentially expanding therapeutic options for this condition. The gene discussed is GCG; the disease is Hypoglycemia.